PCV risk groups: updated patient group direction template
This updated PGD template supports the provision of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals with underlying medical conditions.
Source:
UK Health Security Agency
SPS commentary:
Updated to include addition of note for management of clusters and outbreaks of pneumococcal disease, and information on premature infants and occurrence of apnoea, administration of an additional booster and splenectomy immunisation post bone marrow transplant & timing of vaccination for leukaemia.